Navigation Links
Uroplasty to Present at ROTH Capital Partners 20th Annual OC Growth Stock Conference
Date:2/6/2008

MINNEAPOLIS, Feb. 6 /PRNewswire-FirstCall/ -- Uroplasty, Inc. (Amex: UPI), a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunction, announced today that it will be presenting at the ROTH Capital Partners OC Growth Conference on Wednesday, February 20, 2008 at the Ritz Carlton Laguna Nigel. David Kaysen, Uroplasty's President and CEO and Medi Jiwani, Uroplasty's Vice President and CFO, will present the Company's business strategy and financial results at 4:00 p.m. Pacific Time.

Attendance at the conference is by invitation only. A live audio-only webcast of the presentation will be broadcast via the Internet. Those interested in listening to the webcast may access it at Uroplasty's website at http://www.uroplasty.com. An archived replay of the presentation will also be available shortly after the live presentation at Uroplasty's website.

Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom, is a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions. Our primary focus is the commercialization of our Urgent PC(R) system, which we believe is the only FDA-approved non-surgical neurostimulation therapy for the treatment of overactive bladder symptoms (OAB). We also offer Macroplastique(R) Implants, a bulking agent for the treatment of urinary incontinence. Please visit Uroplasty, Inc. at http://www.uroplasty.com.


'/>"/>
SOURCE Uroplasty, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Uroplasty Expands Marketing Program for Urology Practices
2. Uroplasty, Inc. Announces Pricing of a Public Offering of Its Common Stock
3. Uroplasty, Inc. Reports Record Sales For Second Fiscal Quarter
4. Uroplasty to Host Second Quarter Conference Call on November 1
5. Uroplasty, Inc. Announces Filing of Registration Statement for Offering of Common Stock
6. HMS Holdings Corp. to Present at 2008 UBS Global Healthcare Services Conference
7. West Pharmaceutical Services to Present at the 2008 UBS Global Healthcare Services Conference
8. Sharps Compliance Corp. to Present at the RedChip Small-Cap Investor Conference in Scottsdale, Arizona
9. Vical to Present at BIO CEO and Investor Conference
10. ADVENTRX Pharmaceuticals to Present at The 10th Annual BIO CEO & Investor Conference
11. NPS Pharmaceuticals to Present at BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2017)... ... March 30, 2017 , ... According to the American Society of Plastic Surgeons ... among the top 5 most popular minimally-invasive cosmetic procedures in the country. With summer ... performed over the next 8-10 weeks. For anyone considering a hair removal procedure, there ...
(Date:3/30/2017)... ... March 30, 2017 , ... AudioEducator, a leader in training ... Readmissions Through Discharge Planning ” with noted expert Sue Dill Calloway, RN, MSN, ... strategies to prevent readmissions in light of the most recent programs at the ...
(Date:3/29/2017)... (PRWEB) , ... March 29, 2017 , ... ... and women’s professional squash, announced it has enlisted New York City-based sports and ... agency will develop and procure sponsorship opportunities for the Professional Squash Association (PSA), ...
(Date:3/29/2017)... (PRWEB) , ... March 30, 2017 , ... Sublime Naturals ... "Spice of Life" or "Wonder Spice", it has been used for thousands of years. ... the East," says Heshelow, author of " Turmeric: How to Use it For Your ...
(Date:3/29/2017)... ... March 29, 2017 , ... Based ... into the challenges employers face in trying to balance both short-term and long-term ... programs? Adding to the growing complexity, companies are finding that the short-term ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... , March 29, 2017  Novartis announced today ... has accepted the company,s Biologics License Application (BLA) ... an investigational chimeric antigen receptor T cell (CAR-T) ... young adult patients with B-cell acute lymphoblastic leukemia ... Novartis for a CAR-T. The priority review designation ...
(Date:3/29/2017)... Research and Markets has announced the addition of the "South ... & Forecast" report to their offering. ... The South Korean Proton Therapy Market is expected to ... Untapped Proton Therapy Market for South Korea was ... Proton Therapy plays an important role in delivering comprehensive cancer care to ...
(Date:3/29/2017)... 29, 2017  Zynex (OTCQB: ZYXI), an innovative medical technology ... medical devices for pain management, stroke rehabilitation, cardiac monitoring ... the Company,s 2016 full-year investor webcast on Monday, April 3, ... The Company expects to file its 2016 full year ... ...
Breaking Medicine Technology: